Highlights Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Market Closed - Canadian Securities Exchange Other stock markets 17:35:56 15/05/2024 BST			5-day change	1st Jan Change
1.3 ^CAD	-0.76%		-11.56%	-44.21%

03-26	Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM	CI
03-01	Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Defence Therapeutics Inc. Announces the Successful Testing of Second-Generation Anti-Cancer Vaccine, Called ARM-002TM	03-26	CI
Defence Therapeutics Inc. Announces Peer-Reviewed Publication on Accum-E7 Anti-Cancer Vaccine in Cancer Science Journal and Financing Update	02-29	CI
Defence Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	02-28	CI
Defence Therapeutics Inc. Tests a New Formulation of its ACCUM-002TM Dimer CDCA-SV40 Commonly Named AccuTOX®	01-10	CI
Defence Therapeutics Inc. Receives FDA Approval for Phase I Clinical Trial Targeting Solid Cancer Tumors with Accutox	12-11	CI
Defence Therapeutics Inc. Reports Earnings Results for the First Quarter Ended September 30, 2023	11-24	CI
Defence Therapeutics Inc. Announces Successful Submission of an Investigational New Drug Application for Accutox(R) as an Injectable Anticancer Treatment for Solid Tumors	11-14	CI
Defence Therapeutics Inc. Announces the Discovery of a Novel Function for Its Lead Antigen Injectable Drug AccuTOX	25/10/23	CI
Defence Therapeutics Inc. Announces Novel Accutox(Tm) Continues Toprise on Results Against Cancer	18/10/23	CI
Defence Therapeutics Inc. Announces Peer-Reviewed Publication of its Preclinical Data on Accum as Anti-Cancer Molecule in Journal of Cancer Science	10/10/23	CI
Defence Therapeutics Inc. Announces Accum-mRNA Lipid Nanoparticles Elicit Antibody Response 2X Stronger than Standard mRNA Vaccines	25/09/23	CI
Defence Therapeutics Inc. Successfully Completes the First Milestone of Its Collaboration Agreement with Orano	18/07/23	CI
Defence Therapeutics Inc. and Dennis Quaid Join Forces to Explore Breakthroughs in Biotechnology	04/07/23	CI
Defence Therapeutics Inc. Announces the Publication of Its New International Patent Application Demonstrating the Effectiveness of Defence's AccumTM-Based Technology	20/06/23	CI
Defence Therapeutics Inc. Announces Reach the Final Stages of Its AccuTOX^TM Chemistry, Manufacturing and Controls	16/06/23	CI
Defence Therapeutics Picks Transbiotech to Test Animal Vaccine for Pancreatic Cancer	06/06/23	MT
Defence Therapeutics Inc. Begins Testing Its Arm Vaccine Against Pancreatic Cancer	06/06/23	CI
Defence Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2023	29/05/23	CI
Defence Therapeutics Inc. Announces Successful Completion of Pre-Clinical Study Evaluating the Therapeutic Potency of Second-Generation Arm Vaccine Targeting Solid Tumoma	24/05/23	CI
Defence to Complete A Final Pre-Clinical Study Prior to IND Filings for the AccuTOX(TM) Phase I Cancer Trial At the City of Hope National Medical Center and Beckman Research Institute	28/03/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Defence Therapeutics Inc.

Equities

DTC

CA24463V1013

Highlights

Filters